- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00620594
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
This is a first-in-human, phase I/Ib clinical research study with BEZ235, an inhibitor of phosphatidylinositol 3'-kinase (PI3K). The study consists of a dose escalation part followed by a safety dose expansion part:
Dose escalation part (advanced solid tumors, including patients with breast cancer being treated with trastuzumab):
Patients receive oral BEZ235 once daily on days 1-28 of the first course. Courses will repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of at least 3 patients receive escalating doses of BEZ235, as single agent or in combination with trastuzumab, until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose expected to produce during the first course of treatment dose-limiting toxicity in 33% of patients.
Once the MTD has been defined, the safety expansion parts of the trial will be opened for enrollment.
Safety dose expansion part (advanced solid tumors, including patients with breast cancer being treated with trastuzumab):
Patients will be treated with BEZ235, as single agent or in combination with trastuzumab, given at the MTD, once daily. Treatment of patients will continue until disease progression or occurrence of unacceptable side effects.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Essen, Alemania, 45147
- Novartis Investigative Site
-
-
-
-
Catalunya
-
Barcelona, Catalunya, España, 08035
- Novartis Investigative Site
-
-
Comunidad Valenciana
-
Valencia, Comunidad Valenciana, España, 46010
- Novartis Investigative Site
-
Valencia, Comunidad Valenciana, España, 46009
- Novartis Investigative Site
-
-
-
-
California
-
Los Angeles, California, Estados Unidos, 90095
- University of California at Los Angeles JonssonComprehensiveCancerCtr
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06520
- Yale University School of Medicine YaleCancerCtr-ClinTrialsOffice
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Dana Farber Cancer Institute Clinical Trials ProjectManager
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89135
- Nevada Cancer Institute NVCC - Huntsman
-
-
South Carolina
-
Greenville, South Carolina, Estados Unidos, 29605
- Cancer Centers of the Carolinas CCC Faris
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(2)
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75246
- Baylor Health Care System/Sammons Cancer Center Baylor- Sammons
-
Houston, Texas, Estados Unidos, 77030-4009
- University of Texas/MD Anderson Cancer Center Thoractic Head/Neck Med.Onc(2)
-
Tyler, Texas, Estados Unidos, 75702
- Tyler Cancer Center TCC
-
-
-
-
-
Amsterdam, Países Bajos, 1066 CX
- Novartis Investigative Site
-
-
-
-
-
Manchester, Reino Unido, M20 9BX
- Novartis Investigative Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
[Single agent dose escalation arm]: Patients with histologically-confirmed, advanced unresectable solid tumors including CS patients who have progressed on (or not been able to tolerate) standard therapy within three months before screening visit or for whom no standard anticancer therapy exists.
[Combination part]: Patients with metastatic HER2+ Breast Cancer, after failure of trastuzumab treatment. Eligible patients will have to have tumors carrying molecular alterations of PIK3CA and/or PTEN.
[Single agent safety expansion arm]: Patients with histologically-confirmed, advanced unresectable solid tumors including CS patients who have progressed on (or not been able to tolerate) standard therapy within three months before screening visit or for whom no standard anticancer therapy exists. Patients will be prescreened for molecular alterations affecting PIK3CA and/or PTEN. Patients with NSCLC will also be pre-screened for EGFR mutation.
Exclusion Criteria:
- Patients who have brain metastases, which are progressive and/or requiring medical intervention for symptom control
- Prior treatment with a PI3K inhibitor
- Acute or chronic liver disease or renal disease
- Acute or chronic pancreatitis
- Patients with unresolved diarrhea ≥ CTCAE grade 2
- Impaired cardiac function or clinically significant cardiac diseases
- Patients with diabetes mellitus requiring insulin treatment
- Patients with known coagulopathies
- Patients with a history of photosensitivity reactions to other drugs
- Any of the following ophthalmological findings:
- Progressive eye disease that could lead to severe loss of visual acuity or visual field
- loss during the study period
- Inability to perform the ophthalmic procedures required in this protocol
- Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g. active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol.
Other protocol-defined inclusion/exclusion criteria may apply
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: BEZ235 Alone, Dose Escalation
|
|
Experimental: BEZ235 + trastuzumab, Dose Escalation
|
|
Experimental: BEZ235 Alone, MTD Expansion
|
|
Experimental: BEZ235 + Trastuzumab, MTD Expansion
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
determine the maximum Tolerated Dose (MTD) of BEZ235 as single agent and in combination with trastuzumab (Dose escalation part)
Periodo de tiempo: at end of study
|
at end of study
|
assess the safety & tolerability of BEZ235 SDS as single agent and in combination with trastuzumab administered to patients at the MTD level (Safety expansion part)
Periodo de tiempo: at end of study
|
at end of study
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
assess the safety and tolerability of the various formulations of BEZ235
Periodo de tiempo: at end of study
|
at end of study
|
Asses the Pharmacokinetics of BEZ235 which includes AUC, Cmax, Tmax, t1/2 as endpoints
Periodo de tiempo: at end of study
|
at end of study
|
Preliminary anti-tumor activity (tumor response) of BEZ235 SDS as single agent and in combination with trastuzumab
Periodo de tiempo: end of study
|
end of study
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CBEZ235A2101
- 2006-004353-23 (Número EudraCT)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de mama
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University y otros colaboradoresTerminadoLa guía de aplicación clínica de Conebeam Breast CTPorcelana
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
Ensayos clínicos sobre BEZ235
-
Cliniques universitaires Saint-Luc- Université...NovartisTerminadoCélula de transición de carcinomaBélgica, Luxemburgo
-
Novartis PharmaceuticalsRetiradoPEComa maligno (tumores de células epitelioides perivasculares)España
-
Novartis PharmaceuticalsRetirado
-
Restorbio Inc.Activo, no reclutandoInfecciones del Tracto RespiratorioEstados Unidos
-
Novartis PharmaceuticalsRetiradoCáncer endometrialEstados Unidos, Federación Rusa, Alemania, Singapur, Italia, España, Francia, Brasil, Canadá, Japón, Polonia, Pavo
-
Novartis PharmaceuticalsTerminadoTumor sólido avanzadoJapón
-
Memorial Sloan Kettering Cancer CenterNovartisTerminado
-
Restorbio Inc.RetiradoEnfermedad respiratoria clínicamente sintomática
-
Goethe UniversityTerminadoLeucemia linfoblástica aguda | Leucemia Mielocítica Aguda | Leucemia mielógena crónica con crisis de células blásticasAlemania
-
Medical Research CouncilMerck Sharp & Dohme LLC; Aarhus University Hospital; NCRI Clinical Studies Groups; ECCO - the European CanCer OrganisationDesconocidoGlioblastomaEstados Unidos, Italia, Bélgica, Alemania, Polonia, Federación Rusa, España, Suiza, Ucrania, Reino Unido